SFI
IGC icon

Susquehanna Fundamental Investments’s IGC Pharma IGC Stock Holding History

Susquehanna Fundamental Investments’s Portfolio IGC Stock Details IGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-28,200
Closed -$44K – 1571
2020
Q4 		$44K Buy
+28,200
New +$41.7K ﹤0.01% 1456

Other funds holding IGC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CFA
Carroll Financial Associates Charlotte, North Carolina $1.88B AUM 20.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
DP
Dearborn Partners Chicago, Illinois $1.85B AUM 6.59% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Susquehanna Fundamental Investments's IGC Position: Q1 2021 in Review

Susquehanna Fundamental Investments sold out of IGC Pharma (IGC) in Q1 2021, closing a stake of 28,200 shares — an estimated $44K sold.

Susquehanna Fundamental Investments first reported a position in IGC in Q4 2020 and held it in 1 quarter. The position peaked at $44K in Q4 2020. 29 funds tracked by Wall St. Rank hold IGC as of Q1 2021.

  • Susquehanna Fundamental Investments reported no remaining IGC Pharma position as of Q1 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 28,200 IGC Pharma shares in Q1 2021, an estimated $44K.
  • Susquehanna Fundamental Investments first reported a position in IGC Pharma in Q4 2020 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's IGC Pharma position peaked at $44K in Q4 2020.
  • 29 funds tracked by Wall St. Rank held IGC Pharma as of Q1 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2021, filed 17 May 2021.